Novotech Appoints Anand Tharmaratnam as CEO
January 16, 2026
New leader will be based at the company’s new global headquarters in Singapore
1 min read
False
Advertisement
Latest
Schistosomiasis: The Need for a Tailored-Made Treatment for Preschoolers
January 15, 2026
About the Pediatric Praziquantel Consortium, and why a child-friendly treatment for preschool-aged children with schistosomiasis was needed
13 min read
Why Europe’s CDMO Sector Must Learn to Dance with Disruption
By Joe Renny
January 14, 2026
For CDMOs, the storms of de-industrialization, Brexit, and the Biosecure Act are not existential threats but the very winds that can propel them forward.
4 min read
Does the Role of CDMO Need to Evolve?
By Stephanie Vine
January 14, 2026
In short: Yes, says Mat Minardi, Chief Scientific Officer at Sterling Pharma Solutions
7 min read
Manufacturability and the Winners in Advanced Therapies
By Stephanie Vine
January 13, 2026
Are developers still underestimating the engineering sophistication required to scale advanced therapies in the real world? Alan Boyd discusses.
7 min read
Medable Debuts AI Agent for Automating Trial Master File Processes
January 12, 2026
New capability frees up human capital from one of the biggest labor costs in clinical research
1 min read
The Future of Precision Medicine is Radiopharmaceuticals
By Mona-Elisabeth Rootwelt-Revheim
January 12, 2026
Here’s why so many people in the industry are excited about the potential of radiopharmaceuticals for diagnosis and treatment.
5 min read
The Truth About Softgels: Phthalate-Free, Powered by Glycerin and Sorbitol
By Stephen Tindal
January 9, 2026
Catalent offers clarification after recent discussions raised concerns around softgels, phthalates and potential health risks
3 min read
A Turning Point in MASH
By HH Kim
January 8, 2026
A billion-dollar acquisition, breakthrough clinical data, and a shifting scientific paradigm are pushing MASH out of the shadows and into a new era of metabolic medicine.
3 min read
Inside 2026: The Industry’s AI Turning Point
January 7, 2026
The life sciences sector is bracing for a year when AI delivers real returns, regulators move faster, and trial operations are finally built for modern science.
6 min read
